Chemify
Assembly Line
Chemify Receives Grant to Design and Discover New Drug Leads for Tuberculosis and Malaria Using Digital Chemistry Technology
Chemify, a deep tech chemical science company combining chemistry, robotics and AI at scale to digitally design, discover and make new molecules, announced that it has been awarded a grant from the Bill & Melinda Gates Foundation to discover new drug leads for treating tuberculosis (TB) and malaria. By leveraging the company’s proprietary Chemputation technology and workflow, Chemify aims to deliver unmatched drug design and discovery outcomes and potential drug candidates to positively impact the lives of patients worldwide.
Chemify will design, make, and discover compounds using its Chemputation technology – an automated, seamlessly-controlled digital chemical stack with cheminformatics, robotics and AI to uniquely connect the digital design, planning and multiplexed synthesis of novel small molecules. Potential leads will be iteratively optimized using the Chemputation-driven AI during each development cycle. Lead compounds will then be further analyzed and developed by undisclosed partners.
Chemify Announces $43 Million of Funding to Digitize Chemistry
Chemify, a pioneering company operating its proprietary molecular design, discovery, and chemical manufacturing technology to provide pharmaceutical, biotechnology, and industrial partners with better molecules, today announced funding of $43 million including a Series A led by Triatomic Capital, joined by new investors including Hong-Kong based Horizon Ventures, US-based Rocketship Ventures, Possible Ventures, Alix Ventures, Scotland-based Eos, and the UK Government Innovation Accelerators program. Existing investor BlueYard Capital also participated in the round.
Founded in 2019 by CEO Lee Cronin with backing from David Cleevely (co-founder of Abcam), Chemify is based on decades of chemistry research, robotics, AI, and conceptual advancements from Cronin’s Digital Chemistry Laboratory at the University of Glasgow in Scotland. Professor Cronin’s pioneering research spans the digitization of chemistry including the use of artificial intelligence in chemistry to explore ‘chemical space’ - to access and create the trillions of possible combinations of natural elements. Chemify can help reduce the amount of costly and time-consuming experimentation required to discover promising new molecules, speeding up their development as products to underpin advances in medicine, farming, materials science, and green energy.
⚗️🧠 Chemify Announces $43 Million of Funding to Digitize Chemistry
Chemify, a pioneering company operating its proprietary molecular design, discovery, and chemical manufacturing technology to provide pharmaceutical, biotechnology, and industrial partners with better molecules, today announced funding of $43 million including a Series A led by Triatomic Capital, joined by new investors including Hong-Kong based Horizon Ventures, US-based Rocketship Ventures, Possible Ventures, Alix Ventures, Scotland-based Eos, and the UK Government Innovation Accelerators program. Existing investor BlueYard Capital also participated in the round.
Founded in 2019 by CEO Lee Cronin with backing from David Cleevely (co-founder of Abcam), Chemify is based on decades of chemistry research, robotics, AI, and conceptual advancements from Cronin’s Digital Chemistry Laboratory at the University of Glasgow in Scotland. Professor Cronin’s pioneering research spans the digitization of chemistry including the use of artificial intelligence in chemistry to explore ‘chemical space’ - to access and create the trillions of possible combinations of natural elements. Chemify can help reduce the amount of costly and time-consuming experimentation required to discover promising new molecules, speeding up their development as products to underpin advances in medicine, farming, materials science, and green energy.